Toggle Health Problems and D

Vitamin D Receptor activators (such as paricalcitol) treat dialysis patients similarly – Aug 2017

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.

BMC Nephrol. 2017 Aug 25;18(1):272. doi: 10.1186/s12882-017-0691-6.
Xie Y1, Su P2, Sun Y3, Zhang H4, Zhao R2, Li L2, Meng L2.


Vitamin D Receptor category has the following

470 studies in Vitamin D Receptor category

Vitamin D tests cannot detect Vitamin D Receptor (VDR) problems
A poor VDR restricts Vitamin D from getting in the cells

See also: 44 studies in the Resveratrol category

It appears that 30% of the population have a poor VDR (40% of the Obese )
Several diseases protect themselves by deactivating the Vitamin D receptor.Example: Breast Cancer
- - - - - - - -
The Vitamin D Receptor is associated with many health problems

Health problems include: Autoimmune (17 studies), Breast Cancer (20 studies), Colon Cancer (13 studies), Cardiovascular (22 studies), Cognition (16 studies), Diabetes (22 studies), Hypertension (7 studies), Infant (18 studies), Lupus (6 studies), Metabolic Syndrome (3 studies), Mortality (4 studies), Multiple Sclerosis (11 studies), Obesity (15 studies), Pregnancy (22 studies), Rheumatoid Arthritis (10 studies), TB (8 studies), VIRUS (30 studies),   Click here for details
Some health problems, such as Breast Cancer and Diabetes, protect themselves by reducing VDR activation
Suspect that SAR-COV-2 also protects itself from Vitamin D

55 health problems associated with poor VDR

A poor VDR is associated with the risk of 55 health problems  click here for details
The risk of 48 diseases at least double with poor VDR as of Jan 2023  click here for details
Some health problem, such as Breast Cancer reduce the VDR

VDR at-home test $29 - results not easily understood in 2016
There are hints that you may have inherited a poor VDR

How to increase VDR activation

Compensate for poor VDR by increasing one or more:

1) Vitamin D supplement  Sun
Ultraviolet -B
Vitamin D in the blood
and thus in the cells
2) MagnesiumVitamin D in the blood
 AND in the cells
3) Omega-3 Vitamin D in the cells
4) Resveratrol Vitamin D Receptor
5) Intense exercise Vitamin D Receptor
6) Get prescription for VDR activator
   paricalcitol, maxacalcitol?
Vitamin D Receptor
7) Quercetin (flavonoid) Vitamin D Receptor
8) Zinc is in the VDRVitamin D Receptor
9) BoronVitamin D Receptor ?,
10) Essential oils e.g. ginger, curcuminVitamin D Receptor
11) ProgesteroneVitamin D Receptor
12) Infrequent high concentration Vitamin D
Increases the concentration gradient
Vitamin D Receptor
13) Sulfroaphane and perhaps sulfurVitamin D Receptor
14)Butyrate especially gutVitamin D Receptor

Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above

Far healthier and stronger at age 72 due to supplements Includes 6 supplements that help the VDR

 Download the PDF from VitaminDWiki

Secondary hyperparathyroidism (SHPT) is a severe complication for dialysis patients. Vitamin D receptor activators (VDRAs) are used to treat SHPT, but the comparative efficacy and safety between paricalcitol and other vitamin D receptor activators for management of SHPT in dialysis patients has been unproven.

We searched PubMed, Embase, and the Cochrane Library for the time period through June 2017 to identify randomized controlled trials that evaluated paricalcitol compared with other VDRAs for treatment of SHPT. The primary outcome was the percentage of patients with target reduction of intact parathyroid hormone (iPTH) from baseline. Secondary outcomes included incidences of hypercalcemia and hyperphosphatemia. The random-effects model was used to estimate relative risks (RRs) with 95% confidence intervals (CIs).

Eight studies (N = 759) were eligible for final inclusion. Compared with other VDRAs, no significant differences were found in the percentage of patients with target reduction of intact parathyroid hormone (iPTH) from baseline for paricalcitol treatment of SHPT in dialysis patients (RR, 1.01; 95% CI, 0. 87-1.18; p = 0.85). There were no differences in the incidence of hypercalcemia (RR, 0.95; 95% CI, 0.74-1.21; p = 0. 65) and hyperphosphatemia (RR, 0.94; 95% CI, 0.77-1.16; p = 0.58).

The presently available evidence is insufficient to draw a conclusion regarding whether paricalcitol therapy has a comparative efficacy and safety over other VDRAs for treating dialysis patients with SHPT. Large-sample, well-conducted, high-quality RCTs with patient-level outcomes (i.e., mortality) are urgently needed.

PMID: 28841848 DOI: 10.1186/s12882-017-0691-6

Created by admin. Last Modification: Sunday August 27, 2017 12:11:43 GMT-0000 by admin. (Version 2)

Attached files

ID Name Comment Uploaded Size Downloads
8356 VDRAs.pdf PDF 2017 admin 27 Aug, 2017 11:54 881.93 Kb 490